GlassScriptPhysician profile
Roberto Sirven
NPI 1902235476
$13,130.90
in general payments reported to CMS, 2019-2025
26 companies · $2,900 in 2025
The $2,900 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,211 · 2022: $2,015 · 2023: $2,355 · 2024: $2,650 · 2025: $2,900.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,872 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,871.56 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharming Healthcare, INC. | $2,012.61 | 2021-2025 | Ruconest |
| Glaxosmithkline, LLC. | $1,993.13 | 2021-2025 | Trelegy Ellipta, Nucala |
| Astrazeneca Pharmaceuticals LP | $1,908.90 | 2021-2025 | Fasenra, Airsupra, Tezspire |
| Genzyme Corporation | $1,001.92 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $986.83 | 2021-2025 | Takhzyro, Eohilia |
| Regeneron Healthcare Solutions, INC. | $780.85 | 2021-2025 | Dupixent |
| Biocryst US Sales Co., LLC | $773.49 | 2021-2025 | Orladeyo |
| Optinose US, INC. | $686.19 | 2021-2025 | |
| Csl Behring | $673.77 | 2021-2025 | Haegarda, Andembry |
| Abbvie INC. | $504.05 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $417.59 | 2021-2025 | |
| Amgen INC. | $303.21 | 2022-2025 | Tezspire |
| Galderma Laboratories, L.P. | $242.61 | 2025 | Nemluvio |
| Pfizer INC. | $203.64 | 2021-2023 | |
| Genentech USA, INC. | $171.93 | 2021-2025 | Xolair |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $114.39 | 2021-2024 | Auvi-Q |
| Ars Pharmaceuticals Operations, INC. | $96.39 | 2025 | Neffy |
| Incyte Corporation | $48.43 | 2022 | |
| Hikma Pharmaceuticals USA | $40.65 | 2024-2025 | Ryaltris |
| Teva Pharmaceuticals USA, INC. | $39.21 | 2021 | |
| Paratek Pharmaceuticals, INC. | $34.02 | 2025 | Xhance |
| Aimmune Therapeutics, INC. | $29.83 | 2022 | |
| Blueprint Medicines Corporation | $24.60 | 2025 | Ayvakit |
| Myovant Sciences INC. | $21.67 | 2021 | |
| Phadia US INC. | $16.34 | 2021 | |
| Organon LLC | $4.65 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roberto Sirven listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.